Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

33.62 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data ↗

March 19, 2025

Immunovant's batoclimab showed positive Phase 3 results in MG but won't be pursued for approval as the company shifts focus to its lead asset, IMVT-1402.

Via Benzinga

Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled. ↗

March 19, 2025

The companies reported positive results for their lead asset in patients with two rare diseases.

Via Investor's Business Daily

Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

March 19, 2025

From Roivant Sciences

Via GlobeNewswire

Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

March 18, 2025

From Roivant Sciences

Via GlobeNewswire

Roivant Sciences Q3 Earnings Assessment ↗

February 10, 2025

Via Benzinga

The Analyst Landscape: 5 Takes On Roivant Sciences ↗

November 13, 2024

Via Benzinga

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

March 03, 2025

From Arbutus Biopharma Corporation

Via GlobeNewswire

Tech Stocks Surge, Steelmakers Jump On Trump's 25% Tariffs, Copper Hits 9-Month Highs: What's Driving Markets Monday? ↗

February 10, 2025

Wall Street bounced back on Monday, recovering from Friday's robust decline fueled by tariff concerns, as investors remained focused on strong earnings from the fourth-quarter reporting season while...

Via Benzinga

Topics Government World Trade

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

Price Over Earnings Overview: Roivant Sciences ↗

October 18, 2024

Via Benzinga

4 Analysts Assess Roivant Sciences: What You Need To Know ↗

September 11, 2024

Via Benzinga

Roivant Sciences Tops Q3 Expectations ↗

February 10, 2025

Roivant Sciences posted earnings that exceeded expectations, with substantial progress in its diversified drug pipeline.

Via The Motley Fool

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update

February 10, 2025

From Roivant Sciences

Via GlobeNewswire

Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care

February 03, 2025

Zest is initially focused on treating the millions of Americans with inflammatory skin diseases who are currently overprescribed expensive biologics

From Roivant Sciences

Via GlobeNewswire

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025

January 29, 2025

From Roivant Sciences

Via GlobeNewswire

Earnings Scheduled For February 10, 2025 ↗

February 10, 2025

Via Benzinga

Trump Index: 6 Companies Linked to Trump’s Cabinet Worth Watching

January 28, 2025

President Trump's cabinet is comprised of millionaires, billionaires and leaders in business who founded or led public companies. Here's the TRUMP index stocks.

Via MarketBeat

Topics Government

Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis

December 03, 2024

From Roivant Sciences

Via GlobeNewswire

Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis

December 03, 2024

From Roivant Sciences

Via GlobeNewswire

'I'm One Of You' – How 'Anti-Woke' Warrior Vivek Ramaswamy Became A Billionaire At Only 38 ↗

November 18, 2024

Via Benzinga

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update

November 12, 2024

From Roivant Sciences

Via GlobeNewswire

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024

October 29, 2024

From Roivant Sciences

Via GlobeNewswire

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

October 28, 2024

The acquisition expands Organon’s dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S.

From Roivant Sciences

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 03, 2024

Via Benzinga

Organon, Howmet Aerospace And More: CNBC's 'Final Trades' ↗

October 03, 2024

On CNBC's "Halftime Report Final Trades," Stephen Weiss of Short Hills Capital Partners named ProShares Short QQQ as his final trade.

Via Benzinga

Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B ↗

September 18, 2024

Organon is set to acquire Roivant Sciences' Dermavant Sciences, known for developing immuno-dermatology treatments, including FDA-approved Vtama cream for plaque psoriasis. The deal, valued up to $1.2...

Via Benzinga

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

September 18, 2024

From Roivant Sciences

Via GlobeNewswire

Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer ↗

September 10, 2024

Roivant Sciences has licensed worldwide rights to develop and commercialize Bayer's mosliciguat for an upfront payment of $14 million and up to $280 million in future milestone payments.

Via Benzinga

Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress

September 10, 2024

From Roivant Sciences

Via GlobeNewswire

Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator

September 10, 2024

From Roivant Sciences

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.